Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 17, 2000

View Archived Issues

NIH offers type I TNF receptor regulator for licensing

Wnt protein signaling found to control adipogenesis

Researchers discover protein required for protein translocation in bacteria

Licensing opportunity from NIH: gene amplification in cancer

NIH licensing opportunity: methods to inhibit cell motility

Atrix to use drug delivery technology to develop products for Pfizer

NIH licensing opportunity: system for functional identification of p53 mutations

NIH licensing opportunity: novel methods for MRA use in vessel delineation

CPMP recommends marketing approval for Serono's new treatment of female infertility

Viragen to file IND for Omniferon, enroll additional patients in HCV trial

Tularik initiates phase I study of anti-cytomegalovirus compound

Triangle Pharmaceuticals to proceed with Coactinon development

Novavax begins clinical trials of testosterone HRT

EpiCept to begin clinical development of cancer pain therapy

Zonagen receives SBIR grant to study SPRMs for endometriosis

GPC Biotech and Bayer establish antibacterial collaboration agreement

Swiss agency issues preapproval letter for Forcaltonin

Novartis on schedule for 2001 launch of Zelmac

Novel cell adhesion antagonists described

New compounds interacting with 5-HT4 receptor useful for gastrointestinal disorders

New series of tricyclic vasopressin agonists under study at AHP

New selective 5-HT3 antagonists useful as antiemetics

Novel AMPA antagonists under study at Kyorin

Novel antifungal agents under development at SS Pharmaceutical

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...